[go: up one dir, main page]

WO2020261538A1 - Composition permettant d'abaisser la pression artérielle - Google Patents

Composition permettant d'abaisser la pression artérielle Download PDF

Info

Publication number
WO2020261538A1
WO2020261538A1 PCT/JP2019/025839 JP2019025839W WO2020261538A1 WO 2020261538 A1 WO2020261538 A1 WO 2020261538A1 JP 2019025839 W JP2019025839 W JP 2019025839W WO 2020261538 A1 WO2020261538 A1 WO 2020261538A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood pressure
composition
lowering blood
turmericol
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2019/025839
Other languages
English (en)
Japanese (ja)
Inventor
隆正 内尾
室山　幸太郎
健吾 川▲崎▼
室▲崎▼　伸二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
House Wellness Foods Corp
Original Assignee
House Wellness Foods Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by House Wellness Foods Corp filed Critical House Wellness Foods Corp
Priority to JP2021527279A priority Critical patent/JP7452776B2/ja
Priority to PCT/JP2019/025839 priority patent/WO2020261538A1/fr
Publication of WO2020261538A1 publication Critical patent/WO2020261538A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to a composition for lowering blood pressure.
  • Hypertension is an important risk factor for cerebrovascular diseases such as cerebrovascular disorders and coronary artery diseases, as well as organ disorders such as heart failure and chronic kidney disease, and hypertension in middle age also increases the risk of vascular dementia in old age.
  • systolic blood pressure of less than 120 mmHg
  • the risk of morbidity and mortality such as cerebrocardiovascular, stroke, myocardial infarction, and chronic kidney disease increases ( Non-Patent Document 1). Therefore, lowering the blood pressure of hypertensive persons is important in the prevention of various cardiovascular diseases.
  • turmeric is known to contain a large number of bioactive substances.
  • Patent Document 1 discloses that blood pressure decreased in humans who ingested an herbal composition containing a combination of a turmeric extract having a curcumin concentration of 95% and an extract of another plant.
  • Patent Document 2 discloses that intraperitoneal administration of a fat-soluble extract of turmeric (turmeric oil) containing turmeric and the like to hypertensive rats reduced blood pressure, and Patent Document 2 uses the turmeric oil. It has been disclosed that treatment of rat-derived aorta suppressed norepinephrine-induced vascular constriction.
  • turmeric turmeric oil
  • Patent Document 3 the ethanol extract of turmeric, along with other plant extracts, is described as a component having an action of treating or preventing hypertension.
  • Patent Document 3 does not describe the experimental results supporting that the ethanol extract of turmeric actually has a blood pressure lowering effect.
  • Patent Document 4 describes that a composition containing a spring turmeric precursor is effective in treating hypertension.
  • Non-Patent Document 2 describes that the ethyl acetate extract of turmeric inhibited the activity of angiotensin II converting enzyme, suggesting that it is effective in treating hypertension.
  • Non-Patent Document 3 discloses that when a methanol extract of turmeric was administered to normotensive rats, the blood pressure decreased in a dose-dependent manner.
  • An object of the present invention is to provide a composition effective for lowering blood pressure.
  • the present inventors have found that blood pressure was significantly reduced in humans who ingested tablets containing turmeric extract containing turmericol A, turmericol B and bisacurone every day for 12 weeks, and completed the following invention. ..
  • a composition for lowering blood pressure which contains at least one of Termeronol A, Termeronol B and Bisacurone as an active ingredient.
  • a composition for lowering blood pressure which contains at least one of turmericol A, turmericol B and bisaclone, and contains a turmeric extract of water or a mixed solvent of water and a hydrophilic organic solvent as an active ingredient.
  • the composition for lowering blood pressure according to any one of (1) to (3) which contains 20 ⁇ g or more of turmeronol A and turmeronol B in total per daily intake.
  • the composition for lowering blood pressure according to any one of (1) to (4) which contains 17 ⁇ g or more of turmeronol A per daily intake.
  • composition for lowering blood pressure according to any one of (1) to (6) which contains 80 ⁇ g or more of bisacron per daily intake.
  • a turmeric extract containing water or a mixed solvent of water and a hydrophilic organic solvent containing at least one of turmericol A, turmericol B and bisaclone, or at least one of turmericol A, turmericol B and bisaclone Use for the manufacture of drugs for lowering blood pressure.
  • the composition or medicine for lowering blood pressure preferably contains 20 ⁇ g or more of turmeronol A and turmeronol B in total per daily intake.
  • the blood pressure lowering composition or medicine preferably contains 17 ⁇ g or more of turmeronol A per daily intake.
  • the blood pressure lowering composition or medicine preferably contains 5 ⁇ g or more of Termeronol B per daily intake.
  • the blood pressure lowering composition or medicine preferably contains 80 ⁇ g or more of bisacron per daily intake.
  • the content of curcumin per daily intake is preferably less than 30 mg.
  • a method of lowering blood pressure which comprises administering to a subject in need of lowering blood pressure and lowering blood pressure in the subject.
  • a method for treating or preventing hypertension which comprises administering to a subject in need of treatment or prevention of hypertension, and treating or preventing hypertension in the subject.
  • (13) Water containing at least one of turmericol A, turmericol B and bisacurone, or at least one of turmericol A, turmericol B and bisacurone for lowering blood pressure in a subject in need of lowering blood pressure.
  • a turmeric extract using a mixed solvent of water and a hydrophilic organic solvent.
  • the active compound or the turmeric extract of the above (13) is preferably for lowering blood pressure by administering 20 ⁇ g or more of turmericol A and turmericol B per day to the subject.
  • the active compound or the turmeric extract of (13) is preferably for lowering blood pressure by administering 17 ⁇ g or more of Termeronol A per day to the subject.
  • the active compound or turmeric extract of (13) is preferably for lowering blood pressure by administering 5 ⁇ g or more of Termeronol B per day to the subject.
  • the active compound or the turmeric extract of the (13) is preferably for lowering blood pressure by administering 80 ⁇ g or more of bisacron per day to the subject.
  • the active compound or the turmeric extract of (13) is preferably for lowering blood pressure by administering to the subject so that the daily dose of curcumin is less than 30 mg.
  • a composition for lowering blood pressure is provided.
  • Hidden-lilies refers to plants belonging to the genus Hidden-lilies of the family Hidden-lilies, and specifically, Curcuma longa (autumn turmeric), Curcuma aromatica, Curcuma zedoraia, Curcuma phaeocaulis, Curcuma kwangisinsia, Curcuma kwangisiensis, Therefore, Curcuma longa is particularly preferable.
  • a portion containing a rhizome as turmeric.
  • turmeric used in the present invention is not particularly limited, and may be crushed turmeric, squeezed juice, extracts, processed products thereof, etc., and turmeric extract is particularly preferable. Hereinafter, preferred embodiments of the turmeric extract will be described.
  • the turmeric extract refers to an extract (turmeric extract) of a plant material derived from a plant belonging to the genus Turmeric of the family Zingiberaceae.
  • the turmeric extract is not limited to the solvent extract obtained by extraction with an extraction solvent, but also includes a solvent extract further fractionally purified by column chromatography or the like.
  • the turmeric extract used in the present invention is derived from an extract in which an extraction operation (including a fraction purification operation in the case of fractional purification) has been completed, a concentrate in which a solvent is partially removed from the extract, or an extract. It can be in the form of a dried product from which the solvent has been removed.
  • the removal of the solvent from the extract can be carried out by volatilizing the solvent by heating and / or reducing the pressure. These heating and depressurizing methods are not particularly limited, and for example, conventionally known methods can be used.
  • the plant raw material examples include the rhizomes of turmeric mentioned above, and in particular, the rhizomes of Curcuma longa and the like are preferable.
  • the rhizome one collected from the soil may be used, and an appropriate part of the rhizome may be used as it is, cut into an appropriate size or shape, or in the form of a crushed product.
  • These plant raw materials may be appropriately dried.
  • the extraction solvent water or a mixed solvent of water and a hydrophilic organic solvent can be used.
  • the hydrophilic organic solvent may be a mixed solvent of a plurality of types of hydrophilic organic solvents.
  • Water also includes hot water.
  • hot water for example, hot water having a temperature of 95 ° C. or higher can be used.
  • the hydrophilic organic solvent include at least one alcohol (may be a mixed solvent of a plurality of alcohols), and the alcohol is not particularly limited, but ethanol is preferable.
  • the mixing ratio when a mixed solvent of alcohol and water is used as the extraction solvent is not particularly limited, but for example, the weight ratio is preferably in the range of 10:90 to 90:10, more preferably in the range of 20:80 to 50:50. ..
  • supercritical carbon dioxide can be used as the extraction solvent.
  • the method for extracting turmeric extract from plant raw materials is not particularly limited.
  • a turmeric extract from the extraction solvent containing at least one of turmericol A, turmericol B and bisaclone as the turmeric extract, and the extraction solvent containing at least turmericol A and turmericol B. It is more preferable to use the turmeric extract according to the above, and it is more preferable to use the turmeric extract from the extraction solvent containing turmericol A, turmericol B and bisaclone.
  • Termeronol A and Termeronol B are compounds having the following planar structures, respectively.
  • turmericol A and turmericol B have the S-form configuration of the 6-position carbon in the partial structure of 2-methyl-2-hepten-4-one, but in the present invention, turmericol A and turmericol B may have the above-mentioned planar structure, and the three-dimensional arrangement may be an S body, an R body, or a mixture of an S body and an R body.
  • Bisacurone is a compound having the following planar structure.
  • Bisacurone has an asymmetric carbon at the position marked with * in the planar structural formula and may contain a plurality of optical isomers.
  • Bisacurone may be any optical isomer and two or more kinds. It may be a mixture of optical isomers.
  • At least one of Termeronol A, Termeronol B and Bisacurone used in the present invention may be derived from a plant or may be artificially synthesized. Good.
  • active compound a compound that can be found in Bioscii Biotechnol Biochem. It can be synthesized by the method described in 1993; 57 (7): 1137-40.
  • turmeronol A, turmeronol B, and bisacurone may each have the above-mentioned planar structure, and may be any optical isomer or a mixture of a plurality of optical isomers.
  • the active compound used in the present invention is more preferably derived from a plant raw material, and more preferably derived from a plant belonging to the genus Turmeric of the family Zingiberaceae. Specific examples of plants of the genus Turmeric of the family Zingiberaceae and their sites are as described above.
  • the active compound can be obtained from a site such as a rhizome of a plant belonging to the genus Turmeric of the family Zingiberaceae.
  • the active compound can be extracted from the plant material containing it.
  • the extraction method is as described above.
  • the active compound may be in the form of a plant extract, particularly a turmeric extract with water or a mixed solvent of water and a hydrophilic organic solvent.
  • a fraction obtained by purifying the active compound from the plant extract containing the active compound may be used in the present invention or may be blended in the composition of the present invention.
  • a plant extract containing an active compound can be subjected to a liquid-liquid distribution of ethyl acetate / water to purify the active compound in the ethyl acetate fraction.
  • a plant extract containing an active compound or a fraction thereof can be subjected to a purification treatment by chromatography to obtain a highly purified active compound.
  • chromatography reverse phase column chromatography, normal phase thin layer chromatography and the like can be used.
  • the plant extract containing the active compound or its fraction may be processed by a conventional method such as drying, powdering, granulation, and solution.
  • the active compound preferably contains at least turmeronol A and turmeronol B, and more preferably contains turmeronol A, turmeronol B and bisacurone.
  • composition for lowering blood pressure of the present invention has an action of lowering blood pressure.
  • the blood pressure lowering composition of the present invention has an action of lowering either systolic blood pressure or diastolic blood pressure, and typically has an action of lowering systolic blood pressure.
  • the target of the blood pressure lowering composition of the present invention is typically human, but is not limited to humans and may be other non-human animals such as mammals other than humans.
  • the target of the composition for lowering blood pressure of the present invention is a target that requires lowering of blood pressure, and preferably a target having hypertension or having a blood pressure exceeding a normal value.
  • Targets that require a decrease in blood pressure are, in particular, humans whose systolic blood pressure exceeds normal values, for example, humans whose systolic blood pressure is 130 mmHg or more, and in particular, humans whose systolic blood pressure is 130 mmHg or more and less than 160 mmHg.
  • the composition for lowering blood pressure of the present invention can be used for the prevention or treatment of hypertension.
  • the composition for lowering blood pressure of the present invention is effective not only for subjects suffering from hypertension and subjects with high blood pressure, but also for healthy subjects.
  • the composition for lowering blood pressure of the present invention may be a composition in each form such as a pharmaceutical product, a food or drink, a feed, a food additive, or a feed additive, and is more preferably a pharmaceutical product or a food or drink.
  • Foods and drinks also include foods with functional claims, foods for specified health uses, supplements for nutritional supplements, and the like.
  • composition for lowering blood pressure of the present invention is preferably in the form of a composition ingested or administered orally or nasally, and more preferably in the form of a composition ingested or administered orally.
  • “daily intake” means the total amount of the composition of the present invention ingested or administered in one day, preferably the composition of the present invention by one person, particularly one adult. It means the total amount of an object ingested or administered in one day.
  • the amount of the composition of the present invention is 0.1 g to 500 g in the case of oral or nasal, preferably oral, ingestion or administration. It can be illustrated.
  • the composition of the present invention may be continuously ingested or administered, or may be ingested or administered when necessary.
  • the shape of the composition of the present invention is not particularly limited, and may be any shape such as liquid, fluid, gel, semi-solid, or solid.
  • composition of the present invention may further contain at least one other component in addition to the active compound or the turmeric extract.
  • the composition of the present invention may contain at least one other component, which is not particularly limited, but is preferably accepted in the final form of pharmaceuticals, foods and drinks, feeds, food additives, feed additives and the like. Examples of the components that can be taken orally.
  • Such other components include sweeteners, acidulants, vitamins, minerals, thickeners, emulsifiers, antioxidants, water and the like. Further, if necessary, pigments, fragrances, preservatives, preservatives, fungicides, further bioactive substances and the like may be added.
  • Sweeteners include monosaccharides and disaccharides such as glucose, fructose, sucrose, lactose, maltose, palatinose, trehalose, and xylose, and isomerized sugar (high fructose corn syrup, fructose-fructose syrup, sugar mixed isomerized sugar, etc.) , Sugar alcohol (erythritol, xylitol, lactitol, palatinit, sorbitol, reduced water candy, etc.), honey, high-sweetness sweeteners (sclarose, acesulfam potassium, somatin, stevia, aspartame, etc.) and the like.
  • the acidulant examples include citric acid, malic acid, gluconic acid, tartaric acid, lactic acid, phosphoric acid, and salts thereof, and one or more of these can be used.
  • vitamins examples include vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin E, niacin, inositol and the like.
  • minerals include calcium, magnesium, zinc, iron and the like.
  • thickener examples include carrageenan, gellan gum, xanthan gum, gum arabic, tamarind gum, guar gum, locust bean gum, carrage gum, agar, gelatin, pectin, soybean polysaccharide, carboxymethyl cellulose (CMC) and the like.
  • emulsifier examples include glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, lecithin, vegetable sterol, saponin and the like.
  • antioxidant examples include vitamin C, tocopherol (vitamin E), enzyme-treated rutin and the like.
  • the other ingredients can be appropriately blended in an amount within a range normally adopted by those skilled in the art for compositions such as foods and drinks and pharmaceuticals.
  • the form of the composition obtained by formulating the active compound or the turmeric extract and at least one other component by an appropriate means is a powder, granules, capsules, tablets (coated tablets such as sugar-coated tablets).
  • it may be in the form of a solid composition such as a multi-layer tablet, a disintegrant in the mouth, a chewable tablet, etc., or in the form of a liquid composition such as a solution.
  • composition for lowering blood pressure containing at least one of Termeronol A, Termeronol B and Bisacurone as an active ingredient
  • the content of the active compound or the turmeric extract containing the active compound in the composition for lowering blood pressure of the present invention is not particularly limited, and may be any content effective for lowering blood pressure.
  • the composition for lowering blood pressure according to the present invention is preferably 20 ⁇ g or more, more preferably 37 ⁇ g or more, particularly preferably 55 ⁇ g or more, still more preferably 74 ⁇ g or more, and most preferably 100 ⁇ g or more of Termeronol A per daily intake. And turmeronol B.
  • the composition for lowering blood pressure according to the present invention has a particularly high blood pressure lowering effect.
  • the upper limit of the total content of turmeronol A and turmeronol B is not particularly limited, but the composition for lowering blood pressure according to the present invention typically has a total daily intake of 1100 ⁇ g or less, preferably 550 ⁇ g or less.
  • turmeronol A and turmeronol B preferably 330 ⁇ g or less, particularly preferably 220 ⁇ g or less, still more preferably 170 ⁇ g or less, and most preferably 125 ⁇ g or less.
  • the total amount of turmericol A and turmericol B is in the above range. As such, it is preferable to contain the turmeric extract.
  • the composition for lowering blood pressure according to the present invention contains turmeronol A of preferably 17 ⁇ g or more, more preferably 28 ⁇ g or more, particularly preferably 43 ⁇ g or more, still more preferably 57 ⁇ g or more, and most preferably 77 ⁇ g or more per daily intake. To do.
  • the composition for lowering blood pressure according to the present invention has a particularly high blood pressure lowering effect.
  • the upper limit of the content of turmeronol A is not particularly limited, but the composition for lowering blood pressure according to the present invention is typically 900 ⁇ g or less, preferably 430 ⁇ g or less, more preferably 260 ⁇ g or less, particularly, per daily intake.
  • the composition contains 175 ⁇ g or less, more preferably 130 ⁇ g or less, and most preferably 95 ⁇ g or less of Termeronol A.
  • the composition contains the turmeric extract so that the amount of turmericol A is in the above range. Is preferable.
  • the composition for lowering blood pressure according to the present invention contains turmeronol B of preferably 5 ⁇ g or more, more preferably 8 ⁇ g or more, particularly preferably 12 ⁇ g or more, still more preferably 16 ⁇ g or more, and most preferably 22 ⁇ g or more per daily intake. To do.
  • the composition for lowering blood pressure according to the present invention has a particularly high blood pressure lowering effect.
  • the upper limit of the content of turmeronol B is not particularly limited, but the composition for lowering blood pressure according to the present invention is typically 250 ⁇ g or less, preferably 123 ⁇ g or less, more preferably 74 ⁇ g or less, particularly preferably, per daily intake.
  • the composition contains the turmeric extract so that the amount of turmericol B is in the above range. Is preferable.
  • the composition for lowering blood pressure according to the present invention contains bisacron of preferably 80 ⁇ g or more, more preferably 133 ⁇ g or more, particularly preferably 200 ⁇ g or more, still more preferably 267 ⁇ g or more, and most preferably 360 ⁇ g or more per daily intake. ..
  • the composition for lowering blood pressure according to the present invention has a particularly high blood pressure lowering effect.
  • the upper limit of the content of Bisacurone is not particularly limited, but the composition for lowering blood pressure according to the present invention is typically 4000 ⁇ g or less, preferably 2000 ⁇ g or less, more preferably 1200 ⁇ g or less, particularly preferably 1200 ⁇ g or less per daily intake.
  • the composition when Bisacurone is in the form of a turmeric extract containing it, the composition may contain the turmeric extract so that the amount of Bisacurone is within the above range. preferable.
  • the composition for lowering blood pressure according to the present invention has a curcumin content of less than 30 mg, preferably 5 mg or less, more preferably 2.5 mg or less, and particularly preferably 1.5 mg per daily intake. Hereinafter, it is more preferably 1 mg or less, further preferably 700 ⁇ g or less, and most preferably 520 ⁇ g or less. In this case, the composition for lowering blood pressure according to the present invention has a particularly high blood pressure lowering effect.
  • the composition for lowering blood pressure according to the present invention is preferably a composition that is continuously ingested, specifically, once or twice a day or more, preferably for 4 weeks or more, more preferably. Is a composition that is continuously ingested for 8 weeks or longer, most preferably for 12 weeks or longer.
  • the composition for lowering blood pressure according to the present invention may be the active compound or the turmeric extract itself containing the active compound, the active compound or the turmeric extract containing the active compound, and at least one other component. It may be a composition containing and.
  • the composition of the present invention contains the active compound or the turmeric extract containing the active compound and at least one other component, the active compound or the turmeric extract containing the active compound and at least one other component.
  • the composition may be a mixture of the above components, or the active compound or the turmeric extract containing the active compound and at least one other component may be formulated by an appropriate means.
  • the composition may be a mixture of the active compound or the turmeric extract containing the active compound and a formulated composition of at least one other component, and further mixed with other components.
  • a further aspect of the present invention is water or a mixed solvent of water containing at least one of turmericol A, turmericol B and bisacurone, or at least one of turmericol A, turmericol B and bisacurone, and a hydrophilic organic solvent.
  • the present invention relates to a method for lowering blood pressure, which comprises administering a turmeric extract to a subject in need of lowering blood pressure, and lowering blood pressure in the subject.
  • the active compound or the turmeric extract used in the method according to this embodiment can be in the above-mentioned form of the composition of the present invention.
  • the method according to this aspect may be a medical method or a non-medical method.
  • the target in the method according to this aspect is typically a human, but may be a mammal other than a human.
  • Subjects who require a decrease in blood pressure are preferably those who have hypertension or whose blood pressure is above normal.
  • Targets that require a decrease in blood pressure are, in particular, humans whose systolic blood pressure exceeds normal values, for example, humans whose systolic blood pressure is 130 mmHg or more, and in particular, humans whose systolic blood pressure is 130 mmHg or more and less than 160 mmHg.
  • oral or nasal administration is preferable as the administration route, and oral administration is particularly preferable.
  • the dose of the active compound or the turmeric extract administered to the subject is not particularly limited as long as it is an effective amount for lowering blood pressure.
  • the subject when the subject is an adult, it is preferable to administer the active compound or the turmeric extract to the subject so as to administer a total of 20 ⁇ g or more of turmericol A and turmericol B per day.
  • the subject when the subject is an adult, it is preferred to administer the active compound or the turmeric extract to the subject such that 17 ⁇ g or more of Termeronol A is administered per day.
  • it is preferred to administer the active compound or the turmeric extract to the subject when the subject is an adult, it is preferred to administer the active compound or the turmeric extract to the subject such that 5 ⁇ g or more of Termeronol B is administered per day.
  • the subject when the subject is an adult, it is preferable to administer the active compound or the turmeric extract to the subject so as to administer 80 ⁇ g or more of bisacron per day. Further, it is preferable to administer the active compound or the turmeric extract to the subject so that the daily dose of curcumin is less than 30 mg. More preferably, the active compound or the turmeric is administered so that each active compound in the weight described as a preferable amount of each active compound per daily intake of the composition for lowering blood pressure according to the present invention is administered per day. It is preferable to administer the extract to the subject.
  • turmeric extract was prepared by extracting the rhizome portion of turmeric (Curcuma linga) with water and drying the obtained extract under reduced pressure to remove water.
  • the amounts of turmericol A (TA) and turmericol B (TB) in the turmeric extract were measured using LC / MS, and the amounts of bisacron and curcumin were measured using HPLC.
  • test food is a tablet containing 86.5 ⁇ g of TA, 24.7 ⁇ g of TB, 400 ⁇ g of Bisacurone, and 471 ⁇ g of curcumin per 3 tablets.
  • the test food is a tablet obtained by mixing a turmeric extract, an excipient, a brightener, a coloring agent and a manufacturing agent (fine silicon dioxide, sucrose fatty acid ester) and then tableting.
  • the placebo food is a tablet prepared by substituting the turmeric extract of the above test food with an excipient.
  • FIG. 1 shows the measurement results of systolic blood pressure at each time point.
  • the systolic blood pressure of the group ingesting the test food containing the turmeric extract (turmeric extract group) 4 weeks after ingestion, 8 weeks after ingestion, and 12 weeks after ingestion is as described above. It was significantly lower than the systolic blood pressure at each time point in the group that ingested the placebo food (placebo group). From these results, it was clarified that the intake of turmeric extract lowers blood pressure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition permettant d'abaisser la pression artérielle, comprenant un composant dérivé du curcuma en tant que composant efficace. La présente invention concerne une composition permettant d'abaisser la pression artérielle, comprenant au moins l'un parmi le turméronol A, le turméronol B et la bisacurone. Cette composition permettant d'abaisser la pression artérielle peut contenir un total combiné de 20 μg ou plus de turméronol A et de turméronol B par prise quotidienne, 17 µg ou plus de turméronol A par prise quotidienne, 5 µg ou plus de turméronol B par prise quotidienne et 80 µg ou plus de bisacurone par prise quotidienne.
PCT/JP2019/025839 2019-06-28 2019-06-28 Composition permettant d'abaisser la pression artérielle Ceased WO2020261538A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021527279A JP7452776B2 (ja) 2019-06-28 2019-06-28 血圧降下用組成物
PCT/JP2019/025839 WO2020261538A1 (fr) 2019-06-28 2019-06-28 Composition permettant d'abaisser la pression artérielle

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2019/025839 WO2020261538A1 (fr) 2019-06-28 2019-06-28 Composition permettant d'abaisser la pression artérielle

Publications (1)

Publication Number Publication Date
WO2020261538A1 true WO2020261538A1 (fr) 2020-12-30

Family

ID=74060092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/025839 Ceased WO2020261538A1 (fr) 2019-06-28 2019-06-28 Composition permettant d'abaisser la pression artérielle

Country Status (2)

Country Link
JP (1) JP7452776B2 (fr)
WO (1) WO2020261538A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025018280A1 (fr) * 2023-07-14 2025-01-23 ハウスウェルネスフーズ株式会社 INHIBITEUR DE LA β-SÉCRÉTASE ET COMPOSITION POUR LA PRÉVENTION OU LE TRAITEMENT DE LA DÉMENCE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015160841A (ja) * 2014-02-28 2015-09-07 ハウス食品グループ本社株式会社 エタノールにより誘発される肝障害の抑制剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6312767B2 (ja) * 2016-09-30 2018-04-18 ハウスウェルネスフーズ株式会社 ビサクロン抽出方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015160841A (ja) * 2014-02-28 2015-09-07 ハウス食品グループ本社株式会社 エタノールにより誘発される肝障害の抑制剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADARAMOYE, OLUWATOSIN, A. ET AL.: "Hypotensive and endothelium-independent vasorelaxant effects of methanolic extract from Curcuma longa L. in rats", J ETHNOPHARM, vol. 24, no. 3, 2009, pages 457 - 462, XP026349877 *
LI, JIAN ET AL.: "Structure determination of two new bisabolane-type sesquiterpens from the rhizomes of Curcuma longa by NMR spectroscopy", MAGN RESON CHEM, vol. 53, no. 7, 2015, pages 536 - 538, XP055668665, DOI: 10.1002/mrc4215 *
ZHEN, YONGCHI ET AL.: "New sesquiterpenes and calebin derivatives from Curcuma longa", CHEM PHARM BULL, vol. 55, no. 6, 2007, pages 940 - 943, XP055546620 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025018280A1 (fr) * 2023-07-14 2025-01-23 ハウスウェルネスフーズ株式会社 INHIBITEUR DE LA β-SÉCRÉTASE ET COMPOSITION POUR LA PRÉVENTION OU LE TRAITEMENT DE LA DÉMENCE
JP2025012917A (ja) * 2023-07-14 2025-01-24 ハウスウェルネスフーズ株式会社 β－セクレターゼ阻害剤及び認知症の予防又は治療用組成物

Also Published As

Publication number Publication date
JPWO2020261538A1 (fr) 2020-12-30
JP7452776B2 (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
US11931396B2 (en) Composition for improving vascular endothelial function or improving blood flow in peripheral blood vessels
JP6773361B2 (ja) 気分状態改善剤
JP2019019143A (ja) Ｖｃａｍ−１発現抑制剤
KR102348044B1 (ko) 번아웃증후군의 예방, 개선 또는 치료용 조성물
WO2019203338A1 (fr) Composition contenant du turméronol a et/ou du turméronol b
JP7452776B2 (ja) 血圧降下用組成物
JP6835396B2 (ja) 血中グルコース濃度低減用、血中ヘモグロビンＡ１ｃ量低減用又は血中ＨＤＬ−コレステロール量増加用組成物
JP6709001B1 (ja) ＴＮＦ−α又はＩＬ−６産生抑制用組成物
JP7452777B2 (ja) 生活の質改善又は維持用組成物
JPWO2019221003A1 (ja) がん細胞の増殖抑制用組成物、抗がん用組成物、正常細胞のがん化抑制用組成物、がん発症抑制用組成物、及び、がん細胞死誘導用組成物
CN110621309A (zh) 抗炎用组合物
HK40064821A (en) Composition for lowering blood glucose level, reducing blood hemoglobin a1c content, or increasing blood hdl-cholesterol content
TW202513087A (zh) 腎功能之增進或改善用組合物
HK40076598A (en) At least one of turmeronol a, turmeronol b and bisacurone and use thereof
HK40063023A (en) COMPOSITION FOR INHIBITING TNF-α OR IL-6 PRODUCTION
WO2025018280A1 (fr) INHIBITEUR DE LA β-SÉCRÉTASE ET COMPOSITION POUR LA PRÉVENTION OU LE TRAITEMENT DE LA DÉMENCE
WO2025028304A1 (fr) Compositions atténuant la résistance à l'insuline
HK40063023B (zh) 用於抑制TNF-α或IL-6产生的组合物
JP2022072041A (ja) アドレノメデュリン遺伝子発現増強用組成物
HK40042193A (en) Composition for improving vascular endothelical function or improving blood flow in peripheral blood vessels
JP2022072006A (ja) アドレノメデュリン遺伝子発現増強用組成物
HK40015425A (en) Anti-inflammatory composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19935731

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021527279

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19935731

Country of ref document: EP

Kind code of ref document: A1